MD+DI Readers Rally Behind Axonics for Company of the Year

Last week MD+DI announced Zimmer Biomet as our editors' choice for 2019 Medtech Company of the Year for its impressive turnaround efforts. But as much as we enjoy recognizing our choice each year, it's always fun to see which company is the favorite among our readership. Out of a whopping 2,651 readers who responded to this year's survey, 45.34% (1,202) voted for Axonics Modulation Technologies out of the 10 finalists. Indeed, 2019 was a critical year for Axonics as it won FDA approval for two indications of its implantable rechargeable sacral neuromodulation device. The device is now FDA-approved for the treatment of fecal incontinence, overactive bladder, and urinary retention. The Axonics system is the first rechargeable SNM system approved in Europe, Canada, Australia, and now the United States. The device competes directly with Medtronic's InterStim II device, which has been the standard of care in sacral neuromodulation for the past 22 years. The incumbent is in the process of bringing a new rechargeable version of its technology to the market, both in Europe and the United States. While there has been a significant amount of competitive drama between the two companies, which MD+DI has reported on in recent months, Axonics is clearly not letting Medtronic stand in its way of success. "2019 has been an exc...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news